CliffBio
small molecule

VARUBI

ROLAPITANT HYDROCHLORIDE

Loss of exclusivityJuly 2032latest FDA-listed patent expiry
CompanyTersera Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameVARUBI
Active ingredientROLAPITANT HYDROCHLORIDE
StrengthEQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)
Dosage formEMULSION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalOctober 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
9101615July 2032use U-1741
8470842January 2029use U-1741
7049320August 2028substance, product
7981905April 2027use U-1741
8404702April 2027use U-1741
8178550April 2027substance, product

More from Tersera Therapeutics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VARUBI patent cliff — loss of exclusivity July 2032 | CliffBio